Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
OWLT
Owlet, Inc.
Owlet sells FDA-cleared Medical Devices & Biometrics (Dream Sock and BabySat) with wearable biosensing capabilities.
|
$160.24M |
$5.84
+6.57%
|
|
AIRS
AirSculpt Technologies, Inc.
AirSculpt provides premium, minimally invasive body contouring services through a network of centers, i.e., healthcare services and facilities.
|
$159.84M |
$2.57
-1.15%
|
|
GALT
Galectin Therapeutics Inc.
Lead cancer therapy program belapectin demonstrates oncology-focused Biotech activity and immuno-oncology potential.
|
$157.96M |
$2.44
+8.19%
|
|
MOLN
Molecular Partners AG
Core focus on oncology therapeutics built on the DARPin platform.
|
$157.26M |
$4.29
+2.63%
|
|
MBOT
Microbot Medical Inc.
LIBERTY functions as a vascular/interventional device for endovascular surgery, aligning with Vascular Intervention Devices.
|
$157.15M |
$2.34
-2.09%
|
|
TKNO
Alpha Teknova, Inc.
Teknova is the exclusive US/Canada manufacturer and distributor of the PluriFreeze PF10 cryopreservation system, a medical device.
|
$156.84M |
$2.95
+10.07%
|
|
IMDX
Insight Molecular Diagnostics Inc.
IMDX directly provides Laboratory Testing & Advisory Services via its GraftAssure family (LDTs/kits) for transplant rejection monitoring.
|
$156.84M |
$5.54
+1.19%
|
|
RCEL
AVITA Medical, Inc.
RECELL System and Cohealyx/PermeaDerm are wound care devices used for wound closure and healing.
|
$156.73M |
$5.13
+2.81%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$156.26M |
$2.21
+14.25%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$154.93M |
$2.75
+2.61%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$154.43M |
$3.88
+0.52%
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$154.10M |
$3.23
+1.10%
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$150.13M |
$37.73
+2.65%
|
|
APYX
Apyx Medical Corporation
APYX designs and sells medical devices (Renuvion helium plasma platform and AYON body contouring system) used in surgical procedures.
|
$149.01M |
$4.00
-0.62%
|
|
KPTI
Karyopharm Therapeutics Inc.
Karyopharm's core business is oncology-focused biotechnology/pharmaceuticals, including the approved cancer therapy XPOVIO (selinexor) and an oncology pipeline.
|
$146.81M |
$8.60
-0.75%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$146.26M |
$5.39
+4.26%
|
|
MRSN
Mersana Therapeutics, Inc.
Mersana is an oncology-focused biotechnology company with Emi-Le and XMT-2056 in clinical development.
|
$145.13M |
$29.10
+0.07%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$144.76M |
$8.74
-1.35%
|
|
IPHA
Innate Pharma S.A.
Innate Pharma focuses on oncology therapies, including antibody-based approaches, making Biotech - Oncology a core business area.
|
$144.32M |
$1.64
+1.23%
|
|
KBLB
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories produces recombinant spider silk proteins via transgenic silkworms, a core product category defined as Recombinant Proteins & Enzymes.
|
$142.97M |
$0.14
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$137.57M |
$1.81
+6.76%
|
|
JYNT
The Joint Corp.
The Joint operates chiropractic clinics delivering hands-on care, representing a healthcare services & facilities business.
|
$137.07M |
$9.18
+0.44%
|
|
SLQT
SelectQuote, Inc.
Healthcare Services & Facilities encompasses SelectRx and other healthcare services provided via the platform.
|
$136.87M |
$0.78
+4.65%
|
|
ACNT
Ascent Industries Co.
Custom manufacturing / contract manufacturing services.
|
$133.64M |
$14.20
+1.98%
|
|
HUMA
Humacyte, Inc.
Humacyte's Symvess is a vascular conduit/endovascular device used for extremity vascular trauma—fits Vascular Intervention Devices.
|
$133.00M |
$0.71
+3.74%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$131.50M |
$2.35
-0.42%
|
|
EDAP
Edap Tms S.a.
Focal One is a robotic surgical energy delivery device used for focal therapy of urological cancers.
|
$130.66M |
$3.48
-3.20%
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$130.22M |
$0.78
+4.87%
|
|
ULBI
Ultralife Corporation
Products targeted at medical use (X5 medical care products, wearable power) place Ultralife in Medical Devices & Biometrics.
|
$128.78M |
$7.75
+3.61%
|
|
WALD
Waldencast plc
FDA-approved Obagi saypha MagIQ injectable gel indicates a dermal filler/medical device product line.
|
$128.36M |
$1.04
-1.42%
|
|
HYPR
Hyperfine, Inc.
Hyperfine's Swoop portable MRI is a medical imaging device, directly fitting the Medical Imaging category.
|
$127.29M |
$1.30
-1.88%
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$124.83M |
$2.05
+3.54%
|
|
FONR
FONAR Corporation
Core product offering is the Upright MRI hardware, a specialized medical imaging platform.
|
$123.82M |
$18.79
+0.13%
|
|
TMCI
Treace Medical Concepts, Inc.
Treace's core bunion correction systems are surgical instruments/devices used in operative procedures.
|
$123.61M |
$1.93
+3.21%
|
Showing page 24 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
